Corporate Analysis: iX Biopharma Ltd. (SGX: 42C)

HealthcarePharmaceuticalsTurnaroundDilutionCash FlowAccounting ObservationsSGXCatalist

A visual brief on iX Biopharma's FY2025–9M2026 corporate analysis — covering its proprietary sublingual WaferiX drug-delivery platform, the strategic pivot toward US government contracting, financial performance and cash flow, capital structure and dilution, accounting and disclosure observations, and key risks.

Buy Me a Coffee Back to Library

Want a company covered next?

Suggest a public company for a future OnePage Alpha visual brief. Requests help guide coverage, but do not influence conclusions.

Request a Company

Inside the brief

What this brief covers

Business model

What the company does and how it makes money.

Financial highlights

Revenue, profit, margins, and key operating numbers.

Cash flow quality

Whether accounting profit is supported by cash generation.

Accounting observations

Important notes, adjustments, and disclosure items.

Key risks

Business, funding, operational, and execution risks to monitor.

Questions for management

Practical questions investors can ask before going deeper.

Related briefs

Addvalue Technologies Ltd.

Singapore · Satellite Communications

Equity Research Snapshot: Addvalue Technologies Ltd. (SGX: A31)

A visual brief on Addvalue Technologies’ FY2026 reported turnaround, highlighting revenue growth, operating cash flow improvement, de-leveraging, order book visibility, customer concentration, capitalized development costs, and valuation/event-risk considerations.

Satellite CommunicationsTurnaroundCash FlowDe-leveragingCustomer ConcentrationAccounting ObservationsSGX

View Brief

5HV · SGX1 Jun 2026

Koh Brothers Eco Engineering

Singapore · Construction & Engineering

Koh Brothers Eco Engineering: FY2025 Performance & Risk Dashboard

A visual brief on Koh Brothers Eco Engineering's FY2025 performance and risks — covering its engineering & construction and bio-refinery (Oiltek) segments, segment profitability, financial and balance-sheet health, cash flow, order book visibility, and accounting and disclosure observations.

Construction & EngineeringBio-RefineryCash FlowOrder BookAccounting ObservationsKey RisksSGX

View Brief

Important disclaimer

OnePage Alpha is an educational research project. Content is based on public company disclosures and is provided for informational purposes only. Nothing on this site is financial advice, investment advice, or a recommendation to buy, sell, or hold any security. Readers should verify figures from original source documents and consult a licensed financial adviser where appropriate.